Author: Mokhtari, Reza Bayat; Sambi, Manpreet; Qorri, Bessi; Baluch, Narges; Ashayeri, Neda; Kumar, Sushil; Cheng, Hai-Ling Margaret; Yeger, Herman; Das, Bikul; Szewczuk, Myron R.
Title: The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy Cord-id: k4l5t5s5 Document date: 2021_7_18
ID: k4l5t5s5
Snippet: SIMPLE SUMMARY: Drug development and therapeutic approaches for treating cancer have shifted towards incorporating more multimodality approaches that harness the immune system. Despite innovative and notable advances in immunotherapy, challenges associated with variations in patient response rates and efficacies on select tumors minimize the overall effectiveness of these immunotherapy approaches. This review provides an overview of the current immunotherapy options available, followed by epigen
Document: SIMPLE SUMMARY: Drug development and therapeutic approaches for treating cancer have shifted towards incorporating more multimodality approaches that harness the immune system. Despite innovative and notable advances in immunotherapy, challenges associated with variations in patient response rates and efficacies on select tumors minimize the overall effectiveness of these immunotherapy approaches. This review provides an overview of the current immunotherapy options available, followed by epigenetic immunomodulators that may enhance and transmogrify immunotherapy effectiveness. These approaches are positioned to harness trained immunity, improve immune response rates, and increase the efficacy of immunotherapies. ABSTRACT: Cancer immunotherapy harnesses the immune system by targeting tumor cells that express antigens recognized by immune system cells, thus leading to tumor rejection. These tumor-associated antigens include tumor-specific shared antigens, differentiation antigens, protein products of mutated genes and rearrangements unique to tumor cells, overexpressed tissue-specific antigens, and exogenous viral proteins. However, the development of effective therapeutic approaches has proven difficult, mainly because these tumor antigens are shielded, and cells primarily express self-derived antigens. Despite innovative and notable advances in immunotherapy, challenges associated with variable patient response rates and efficacy on select tumors minimize the overall effectiveness of immunotherapy. Variations observed in response rates to immunotherapy are due to multiple factors, including adaptative resistance, competency, and a diversity of individual immune systems, including cancer stem cells in the tumor microenvironment, composition of the gut microbiota, and broad limitations of current immunotherapeutic approaches. New approaches are positioned to improve the immune response and increase the efficacy of immunotherapies, highlighting the challenges that the current global COVID-19 pandemic places on the present state of immunotherapy.
Search related documents:
Co phrase search for related documents- absence presence and activated state: 1, 2
- absence presence and activity regulate: 1
- absence presence and adaptive immune response: 1, 2
- absence presence and adaptive immune system: 1
- absence presence and adaptive innate: 1, 2
- absence presence and adaptive innate immune response: 1
- absence presence and additional insight: 1
- absence presence and additional insight provide: 1
- absence presence and additional research: 1
- absence presence and adenoviral vector: 1
- absence presence and adrenal medulla: 1
- absence presence and local treatment: 1, 2
- absence presence and long term protection: 1, 2
- absence presence and lung cancer: 1, 2, 3, 4
- absence presence and lung epithelial cell: 1
- absence presence and lymphoid cell: 1, 2
- absence presence and macrophage dendritic cell: 1
- absence presence and macrophage lineage: 1
- absence presence and macrophage neutrophil: 1
Co phrase search for related documents, hyperlinks ordered by date